***The CARES Approach:***

***Improving Glycemic, Cardiovascular, and Renal Outcomes***

**TOOLKIT**

**Overview of Diabetes and Diabetic Care**

|  |  |
| --- | --- |
| Resource | Address |
| Centers for Disease Control and Prevention (CDC). Diabetes State Burden Toolkit: Health Burden.  | <https://nccd.cdc.gov/Toolkit/DiabetesBurden/Home/Health>  |
| Centers for Disease Control and Prevention (CDC). National Diabetes Statistics Report—2020. | <https://www.cdc.gov/diabetes/data/statistics/statistics-report.html> |
| Centers for Disease Control and Prevention (CDC). National Diabetes Statistics Report—2017. | <https://dev.diabetes.org/sites/default/files/2019-06/cdc-statistics-report-2017.pdf> |
| Afkarian M, et al. Clinical manifestations of kidney disease among US adults with diabetes, 1988-2014. *JAMA*. 2016;316:602-610. | <https://jamanetwork.com/journals/jama/fullarticle/2542635>  |
| American Diabetes Association (ADA). 10. Cardiovascular disease and risk management: standards of medical care in diabetes-2020. *Diabetes Care.* 2020;43(suppl 1):S111-S134. | <https://care.diabetesjournals.org/content/43/Supplement_1/S111> |
| American Diabetes Association (ADA). 11. Microvascular complications and foot care: Standards of medical care in diabetes-2019. *Diabetes Care.* 2019;42(suppl 1):S124-S138. | <https://care.diabetesjournals.org/content/42/Supplement_1/S124> |
| American Diabetes Association (ADA). 12. Older adults: Standards of medical care in diabetes-2019. *Diabetes Care.* 2019;42(suppl 1):S139-S147. | <https://care.diabetesjournals.org/content/42/Supplement_1/S139> |
| Davies MJ, et al. Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). *Diabetes Care.* 2018;41:2669-2701. | <https://care.diabetesjournals.org/content/41/12/2669> |
| Defronzo RA. From the triumvirate to the ominous octet: A new paradigm for the treatment of type 2 diabetes mellitus. *Diabetes*. 2009;58:773-795. | <https://diabetes.diabetesjournals.org/content/58/4/773> |
| Moghissi E. Management of type 2 diabetes mellitus in older patients: current and emerging treatment options. *Diabetes Ther*. 2013;4:239-256. | [https://link.springer.com/article/10.1007%2Fs13300-013-0039-6](https://link.springer.com/article/10.1007/s13300-013-0039-6)  |
| National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Diabetes in America, 3rd edition. 2018. | <https://www.niddk.nih.gov/about-niddk/strategic-plans-reports/diabetes-in-america-3rd-edition>  |

**Diabetes and Cardiovascular and Renal Risks**

|  |  |
| --- | --- |
| Resource | Address |
| Arnett DK, et al. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *J Am Coll Cardiol.* 2019;74:e177-e232. | <https://www.ahajournals.org/doi/10.1161/CIR.0000000000000677>  |
| Buse JB, et al. 2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). *Diabetes Care.* 2020;43:487-493. | <https://care.diabetesjournals.org/content/43/2/487> |
| Inzucchi SE. Update on diabetes drugs and CVD risk. American Diabetes Association (ADA). Presented at 64th Advanced Postgraduate Course, February 19, 2017. | <https://professional.diabetes.org/sites/professional.diabetes.org/files/media/inzucchi_update_on_diabetes_drugs_and_cvd_risk_final.pdf>  |
| Inzucchi SE. Personalizing glucose-lowering therapy in patients with type 2 diabetes and cardiovascular disease. *Endocrinol Metab Clin North Am.* 2018;47:137-152.  | <https://www.sciencedirect.com/science/article/abs/pii/S0889852917301160> |
| Kristensen SL, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. *Lancet Diabetes Endocrinol*. 2019;7:776-785. | [https://www.thelancet.com/journals/landia/article/PIIS2213-8587(19)30249-9/fulltext](https://www.thelancet.com/journals/landia/article/PIIS2213-8587%2819%2930249-9/fulltext) |
| Zelniker TA, et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. *Lancet.* 2019;393:31-39. | [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(18)32590-X/fulltext](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2818%2932590-X/fulltext) |

**Cardiovascular (CVOT) Clinical Trials in Diabetes**

|  |  |
| --- | --- |
| Resource | Address |
| CANVAS NCT01032629 | <https://clinicaltrials.gov/ct2/show/NCT01032629> |
| CARMELINANCT01897532  | <https://clinicaltrials.gov/ct2/show/NCT01897532> |
| CAROLINANCT01243424  | <https://clinicaltrials.gov/ct2/show/NCT01243424> |
| CREDENCE NCT02065791  | <https://clinicaltrials.gov/ct2/show/NCT02065791> |
| DECLARE NCT01730534  | <https://clinicaltrials.gov/ct2/show/NCT01730534> |
| ELIXANCT01147250 | <https://clinicaltrials.gov/ct2/show/NCT01147250> |
| EMPA-REG NCT01131676  | <https://clinicaltrials.gov/ct2/show/NCT01131676> |
| EXAMINENCT00968708 | <https://clinicaltrials.gov/ct2/show/NCT00968708> |
| EXSCEL NCT01144338  | <https://clinicaltrials.gov/ct2/show/NCT01144338> |
| HARMONY NCT02465515  | <https://clinicaltrials.gov/ct2/show/NCT02465515> |
| LEADER NCT01179048  | <https://clinicaltrials.gov/ct2/show/NCT01179048> |
| REWIND NCT01394952 | <https://clinicaltrials.gov/ct2/show/NCT01394952> |
| SAVORNCT01107886 | <https://clinicaltrials.gov/ct2/show/NCT01107886> |
| SUSTAIN 6NCT01720446  | <https://clinicaltrials.gov/ct2/show/NCT01720446> |
| TECOSNCT00790205  | <https://clinicaltrials.gov/ct2/show/NCT00790205> |
| VERTIS CV NCT01986881  | <https://clinicaltrials.gov/ct2/show/NCT01986881> |
| PIONEER 6NCT02692716 | <https://clinicaltrials.gov/ct2/show/NCT02692716>  |

**Patient Resources**

|  |  |
| --- | --- |
| Resource | Address |
| American Diabetes Association (ADA). Resources. | <https://www.diabetes.org/resources>  |
| American Diabetes Association (ADA). Tools and Resources. | <https://www.heart.org/en/health-topics/diabetes/diabetes-tools--resources>  |
| American Heart Association (AHA). Prediabetes Tools and Resources.  | <https://www.heart.org/en/health-topics/diabetes/diabetes-tools--resources/prediabetes-tools-and-resources>  |
| Association of Diabetes Care and Education Specialists (ADCES). Resources for People Living with Diabetes. | <https://www.diabeteseducator.org/living-with-diabetes>  |
| Centers for Disease Control and Prevention (CDC). National Diabetes Education Program.  | <https://www.cdc.gov/diabetes/ndep/index.html>  |